MK-677 Side Effects and Safety

MK-677's side-effect profile follows directly from its mechanism: because it activates the ghrelin receptor systemically and continuously (rather than in a brief pulse), the most consistently reported effects across trials are increased appetite, mild fluid retention/edema, and transient lower-extremity numbness or tingling in some subjects. These are considered mechanistic, the same receptor that drives GH release also drives hunger signaling in the hypothalamus. Human data: Human exposure includes multiple randomized, placebo-controlled trials, notably a 2-year study in adults over 60 (Nass et al., 2008), among the longest continuous human safety datasets of any GH secretagogue discussed in this library. That trial reported a modest increase in fasting glucose and insulin resistance markers in the treatment group relative to placebo, without crossing into diagnosed diabetes; glucose monitoring is the most consistently recommended precaution in the literature. Regulatory status: Not approved for human use by the FDA or any regulatory agency for any indication; it remains an investigational compound sold as a research chemical. It has been evaluated in GH-deficiency, sarcopenia, and cachexia research programs without reaching approval. Contraindications commonly cited in research protocols include active malignancy (GH/IGF-1 elevation is a theoretical concern in hormone-sensitive or GH-sensitive tumor growth), pregnancy, and uncontrolled diabetes given the observed effect on insulin sensitivity.